Oculis Holding AG released its financial results for the first quarter ended March 31, 2025, on May 8, 2025. The company reported revenues of $0.32 million, an increase from $0.27 million in the prior-year quarter. However, the net loss for the period widened to CHF 33.2 million, a 106.2% increase from CHF 16.1 million in Q1 2024.
Research and Development (R&D) expenses for the quarter were $18.1 million, a slight decrease from $18.2 million in Q1 2024, while General and Administrative (G&A) expenses increased to $7.4 million from $6.9 million. The widening net loss reflects the continued significant investments in advancing Oculis' clinical development programs.
Operationally, Oculis highlighted the completion of randomization for over 800 patients in both Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01. The company also initiated the first-ever genotype-based development program in ophthalmology with Licaminlimab (OCS-02) and announced promising neuroprotective data with Privosegtor (OCS-05) from the ACUITY trial, which validates its approach in acute optic neuritis and allows for expansion into broader neuro-ophthalmology indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.